## **Snake Bite Treatment**

Allis Hamby, PharmD PGY-1 Resident: Ascension St. Vincent's Birmingham courtney.hamby@ascension.org

#### **Speaker Disclosure**

*I have no financial relationships or affiliations to disclose.* 



## **Objectives**

- Identify the different types of venomous snakes native to our area
- Analyze a patient for indications to treat with antivenom for Pit Viper snake bites
- Initiate an appropriate evidence based medicine treatment regimen that includes appropriate
  - Initial and Maintenance Dosing
  - Safety and Efficacy Monitoring
  - Discharge Counseling
  - Follow-up Visits




## Epidemiology

- Worldwide
  - 2.5 million envenomations per year
  - 81,000-138,000 deaths per year
- United States
  - 7,000-8,000 venomous snakes bites per year
  - Average of 5 deaths per year
- In Alabama, on average 1 person dies every 10 years



### **Snake Facts**


- Optimal Temperature Range
- Striking Range and Top Speed
- Baby Snakes
- Amount of Venom Released





## **Snakes in Alabama**


- 43 different species of snakes
- Only 6 snake species are venomous
  - Pit Vipers and Coral Snake



### **Pit Viper**

- Five of the six venomous snakes in Alabama are in the pit viper (crotalinae) group
  - Eastern Diamondback Rattlesnake, Timber Rattlesnake,
     Pigmy Rattlesnake, Copperhead, and Cottonmouth
- Pit vipers get their name from the presence of pits on both sides of the face between the eye and nostril
- Pit vipers have vertical or "cat-like" pupils, thin necks, triangular heads, and heavy bodies
- Pit vipers are also characterized by having retractable, hollow fangs near the front of the mouth





https://www.aces.edu/blog/topics/forestry-wildlife/identification-and-control-of-snakes-in-alabama/.



Eastern Diamondback Rattlesnake



Timber Rattlesnake



Pygmy Rattlesnake



Copperhead




Cottonmouth



https://www.aces.edu/blog/topics/forestry-wildlife/identification-and-control-of-snakes-in-alabama/.

### **Coral Snake**

- Located mostly in coastal areas
- Close relative of the cobra
- Small head, round pupils, and a slender body
- "Red on yellow, kill a fellow. Red on black, friend of Jack. Black on snout, look out!"



https://www.aces.edu/blog/topics/forestry-wildlife/identification-and-control-of-snakes-in-alabama/.



## **Envenomation**

## **Dry Bites**

- A very small amount of venom or no venom is injected which may cause slight bleeding, pain, and swelling at the bite injury
- 20-25% of bites are dry
- If no symptoms are present within 8 to 12 hours, the snake might not have injected any venom



## **Level of Severity**

Category	Tissue effect	Systemic signs and symptoms	Coagulopathy and bleeding
Minimal	Swelling, pain, and ecchymosis adjacent to the bite site	None	Normal coagulation parameters¶; no bleeding
Moderate	Swelling, pain, and ecchymosis less than full extremity or less than 50 cm if bite on head, neck, or trunk	Present but not life-threatening (eg, nausea, vomiting, diarrhea, oral paresthesia, unusual tastes, tachycardia, tachypnea, mild hypotension [eg, systolic BP >90 mmHg in an adult or >5th percentile for age in children])	Abnormal coagulation parameters <sup>¶</sup> ; no bleeding or minor hematuria, gum bleeding, and/or epistaxis
Severe	Swelling, pain, ecchymosis involving more than the entire extremity; greater than 50 cm if bite on head, neck, or trunk; threatens the airway; OR signs of compartment syndrome	Present and life-threatening (eg, respiratory insufficiency, marked tachycardia for age with severe hypotension, obtundation, seizures)	Markedly abnormal coagulation parameters <sup>¶</sup> with serious bleeding

https://www.uofmhealth.org/health-library/th142



## **Snake Bite Severity Score**

Pulmonary symptoms         No symptoms/signs         Dyspnea, minimal chest tightness, mild or vague discomfort, or respirations of 20-25 breaths/minute         Moderate respiratory distress [tachypnea, 26-40 breaths/minute; accessory muscle use]         Cyanosis, air hunger, extreme tachypnea, or respiratory insufficiency/failure	Criterion Points 0 1 2 3	Gastrointestinal system  No symptoms/signs Pain, tenesmus, or nausea Vomiting or diarrhea Repeated vomiting, diarrhea, hematemesis, or hematochezia Hematologic symptoms No symptoms	0 1 2 3
<ul> <li>Cardiovascular system</li> <li>No symptoms/signs</li> <li>Tachycardia [100-125 BPM], palpitations, generalized weakness, benign dysrhythmia, or hypotension</li> <li>Tachycardia [126-175 BPM]</li> <li>Extreme tachycardia [&gt;175 BPM], hypotension, malignant dysrhythmia, or cardiac arrest</li> </ul>	0 1 2 3	<ul> <li>No symptoms/signs</li> <li>Coagulation parameters slightly abnormal: PT 13-20 secs; PTT 36.5-50 secs; PLTs 100-150K/mL; or fibrinogen 100-150 mcg/mL</li> <li>Coagulation parameters abnormal: PT 20-50 secs; PTT 50-75 secs; PLTs 50-100K/mL; or Fibrinogen 50-100 mcg/mL</li> <li>Coagulation parameters abnormal: PT 50-100 secs; PTT 75-100 secs: PLTs 20-50K/mL; or Fibrinogen &lt;50 mcg/mL</li> <li>Coagulation parameters markedly abnormal, with serious bleeding or the threat of</li> </ul>	
<ul> <li>Local wound</li> <li>No symptoms/signs</li> <li>Pain, swelling, or ecchymosis within 5-7.5 cm of bite</li> <li>Pain, swelling or ecchymosis involving less than half the extremity [7.5-50 cm from bite]</li> <li>Pain, swelling or ecchymosis involving half to all of extremity [50-100 cm from bite]</li> <li>Pain, swelling or ecchymosis extending beyond affected extremity [more than 100cm from bite]</li> </ul>	0 1 2 3 4	spontaneous bleeding; unmeasurable PT or PTT: PLTs <20K/mL; or undetectable fibrinogen; severe abnormalities of other laboratory values also fall into this category <b>Central nervous system</b> • No symptoms/signs • Minimal apprehension, headache, weakness, dizziness, chills, or paresthesia • Moderate apprehension, headache, weakness, dizziness, chills, paresthesia, confusion, or fasciculation in area of bite site • Severe confusion, lethargy, seizures, coma, psychosis, or generalized fasciculation	0 1 2 3

https://www.universityhealthsystem.com/-/media/Files/Clinical-Pathways/Snakebite-Severity-Score-Flowsheet-Algorithm.ashx

## **First-Aid**

#### D0's

- Call 911
- Take a photograph of the snake
- Remove rings and watches
- Wash the bite with soap and water
- Cover the bite with a clean, dry dressing.
- Mark the leading edge of tenderness/swelling on the skin and write the time alongside it

#### DON'Ts

- Do not pick the snake up
- Do not wait for symptoms to appear
- Do not apply a tourniquet
- Do not slash the wound with a knife
- Do not try to suck out the venom.
- Do not apply ice or immerse the wound in water
- Do not drink alcohol as a painkiller
- Do not take pain relievers (such as aspirin, ibuprofen, naproxen)



## **Initial Treatment**

- Gather subjective information
- Mark leading edge of swelling and tenderness every 15-30 minutes
- Immobilize and elevate extremity
- Treat pain (IV opioids preferred)
- Update tetanus
- Call Poison Control (1-800-222-1222)

- Obtain initial lab studies
  - Complete blood count (CBC)
  - Complete metabolic panel (CMP)
  - Serum creatine kinase (CK)
  - Prothrombin time (PT)
  - International normalized ratio (INR)
  - Fibrinogen
  - D-dimer
  - Electrocardiogram (ECG)



## **Check for Signs of Envenomation**

- Check for Signs of Envenomation
  - Swelling, tenderness, redness, ecchymosis, or blebs at the bite site
  - Prolonged prothrombin time, decreased fibrinogen level or decreased platelets
  - Systemic signs, such as hypotension, bleeding beyond the puncture site, refractory vomiting, diarrhea, angioedema, neurotoxicity
- If none of the above signs: Dry Bite/ No Bite
  - Do not administer antivenom
  - Observe patient  $\ge$  8 hours
  - Repeat labs prior to discharge



## Indication for Antivenom

- Swelling that is more than minimal and that is progressing
- Abnormal laboratory coagulation parameters
- Any systemic signs
- If none of the above is present
  - Do not administer antivenom
  - Observe patient 12-24 hours
  - Repeat labs at 4-6 hours and prior to discharge



## **Antivenom Agents**

#### **2 FDA Approved Options**

- Anavip (crotalidae immune F(ab)<sub>2</sub>) (Fab2AV)
  - FDA approved May 2015: Rattlesnake envenomation
  - FDA approved April 2021: All North American Pit Viper envenomation

#### CroFab (crotalidae polyvalent immune fab) (FabAV)

- FDA approved October 2000: Mild-moderate pit viper envenomation
- FDA approved 2009: Severe pit viper envenomation



## **Antivenom Development**

	Anavip	CroFab
Animal Source	Horse	Australian Sheep
Venom Used	Fer-de-lance Central American Rattlesnake Western Diamondback Eastern Diamondback MoJave Rattlesnake Copperhead Cottonmouth	Western Diamondback Eastern Diamondback Mojave Rattlesnake Cottonmouth




## **Antivenom Comparison**

Spectrum of Activity: Anavip and CroFab

- Eastern Diamondback Rattlesnake
- Timber Rattlesnake
- Pigmy Rattlesnake
- Copperhead
- Cottonmouth

98% of venomous snakebites in the United States are from the North American Pit Viper



## **Preparation and Administration**

	Anavip	Crofab
Storage	Up to 25 °C (77 °F) for up to 3 years	$2^\circ$ to $8^\circ C$ (36° to 46°F) for 60 months
Reconstitution	10 mL normal saline per vial	18 mL normal saline per vial (slowly)
	Swirl for 8-26 seconds until fully mixed	Invert for 3-6 minutes until fully mixed
	Use within 6 hours	Use within 4 hours
Fluid	250 mL 0.9% NaCl	250 mL 0.9% NaCl
Infusion time	60 minutes	60 minutes



#### Comparison of F(ab')<sub>2</sub> versus Fab antivenom for pit viper envenomation: A prospective, blinded, multicenter, randomized controlled trial

- 123 patients
- Three comparison groups
  - Anavip<sup>®</sup> + maintenance dosing: 10 vials x1, then 4 vials q6h x 3 doses
  - Anavip<sup>®</sup> + placebo maintenance: 10 vials x1, then 250 ml NS q6h x 3 doses
  - CroFab<sup>®</sup> + maintenance: 5 vials q2h until initial control, then 2 vials q6h x 3 doses
- Primary efficacy endpoint
  - Coagulopathy after the last maintenance dose
  - Defined as platelets <150,000/mm<sup>3</sup> or fibrinogen
     <150 mg/dL, or the use of antivenom between the end of maintenance and study day 5</li>
- 102 patients were bitten by either a rattlesnake or unidentified snake

- Primary endpoint results:
  - Anavip/Anavip vs CroFab/CroFab: 4 (10.3) vs 11 (29.7); p <0.05; ARR 0.195 (0.014 - 0.367); NNT ~5
  - Anavip/placebo vs CroFab/CroFab: 2 (5.3) vs 11 (29.7); p< 0.05; ARR 0.245 (0.073 - 0.410); NNT ~4
- Conclusion
  - For envenomation by North American Pit Viper snakes, this study found that management with longer-half-life Anavip antivenom reduces the risk of post-treatment recurrence and late-onset coagulopathies following treatment when compared with management with CroFab.



## **Antivenom Dosing**

### **Phase 1: Initial Control**

Determine if Initial Control of Envenomation has been Achieved

- Swelling and tenderness not progressing
- Prothrombin, fibrinogen, and platelets normal or clearly improving
- Clinically stable
- Neurotoxicity resolved or clearly improving

### **Phase 2: Maintenance Phase**

- Maintenance therapy is additional antivenom given after initial control to prevent recurrence of limb swelling
- Maintenance therapy may not be indicated in certain situations, such as
  - Minor envenomations
  - Facilities where close observation by a physician expert is available.
  - Not routinely used with Anavip
- Follow local protocol or contact a poison center or physician-expert for advice



#### Anavip (crotalidae immune F(ab)<sub>2</sub>) (Fab2AV) Dosing



https://anavip-us.com/




## Anavip (crotalidae immune F(ab)<sub>2</sub>) (Fab2AV)

- Contraindications: none
- Efficacy
  - Monitor for ≥18 hours following initial control of signs and symptoms
  - Size of bite area (every 15 to 30 minutes)
  - $\circ$  Vital signs
  - CBC, platelet count, fibrinogen levels, and coagulation times (evaluated every 6 hours until patient is stable)

- Safety
  - Pruritus
  - Nausea/vomiting
  - Rash
  - Arthralgia
  - Peripheral edema
  - Erythema
  - Headache
  - Myalgia
  - Pain in extremity



#### Crofab (crotalidae polyvalent immune fab) (FabAV) Dosing



Administer an initial dose of 4-6 vials\* and monitor for signs of progression.

- · Administer an additional 4-6 vials if initial control is not achieved ~1 hour after initial dose
- Once initial control is achieved, administer an additional 2 vials every 6 hours for up to 18 hours (total of 3 doses)

scension

Scheduled maintenance dosing reduced the incidence of coagulation abnormalities due to residual venom<sup>1</sup>

https://crofab.com/ \*Initial dose may vary from 4-12 vials based on clinical judgment and severity of envenomation. Dosing is the same in adult and pediatric patients.

## Crofab (crotalidae polyvalent immune fab) (FabAV)

- Contraindications:
  - History of hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks of anaphylaxis
- Monitoring Parameters
  - Size of bite area (every 15 to 30 minutes)
  - Vital signs
  - CBC, platelet count, fibrinogen levels, and coagulation times (evaluated every 6 hours until patient is stable)

- Safety
  - Urticaria/rash/pruritus
  - Hypotension
  - Nausea
  - Cough
  - Dyspnea
  - Wheezing
  - Hypersensitivity reaction (5%–19%)
  - Serum sickness (5%)
  - Disease-related concerns: recurrent coagulopathy



## When to Call a Physician-Expert

Direct consultation with a physician-expert is recommended in certain high-risk clinical situations:

- Life-threatening envenomation
  - Shock
  - Serious active bleeding
  - Facial or airway swelling
- Hard to control envenomation
  - Requires more than 2 doses of antivenom for initial control
- Recurrence or delayed-onset of venom effects

- Allergic reactions to antivenom
- If transfusion is considered
- Uncommon clinical situations
  - Bites to the head and neck
  - Rhabdomyolysis
  - Suspected compartment syndrome
  - Venom-induced hives and angioedema
- Complicated wound issues

Physician-expert can be reached through a poison center (1-800-222-1222) or a CroFab expert at (1-877-377-3784)

## Discharge Counseling

- Instruct patient to return for:
  - $\circ$   $\quad$  Worsening swelling that is not relieved by elevation
  - Abnormal bleeding
- Instruct patient to seek care if symptoms of serum sickness develop
- Bleeding precautions for 2 weeks in patients with:
  - Rattlesnake envenomation
  - Abnormal prothrombin time, fibrinogen, or platelet count at any time



## **Follow-Up Visits**

- Follow-up visit for Anavip
  - Monitor patients with follow-up visits for signs and symptoms of delayed allergic reactions or serum sickness

- Follow-up visits for CroFab
  - Copperhead victims: PRN only
  - Other snakes: follow up with labs twice (2-3 days and 5-7 days), then as needed

## **Patient Cases**



### **Patient Case: AH**

AH is a 19 yo male presenting to the ED via ambulance for a snake bite. He was bitten approximately 1 hour ago by an unknown snake with rattles. The patient applied a tourniquet.

BP 126/72, HR 80, RR 18, Temp 98.2°, 100kg, 182cm

Allergy: None PMH: None

Labs: WNL

What are the appropriate next steps?

- A. Give the initial dose of antivenom
- B. Discharge patient home
- C. Watch and observe the foot for swelling for 8 hours and repeat labs in 6 hours
- D. Open wound to drain venom



### **Patient Case: RC**

RC is a 35 yo male presenting to the ED via his personal car with a snake bite. He was bitten approximately 30 minutes ago. He did not provide any first aid.

BP 100/65, HR 100, RR 18, 98.9°, 120 kg, 182 cm

Allergy: PCN PMH: HTN, T2DM

Labs: Plt 120, PT 15.3

What is the most appropriate management for this bite?

- A. Wait and watch since the swelling has not progressed to the entire extremity
- B. Administer the initial dose of antivenom





# **Questions?**

## References

- 1. Venomous Snakes. Centers for Disease Control and Prevention. https://www.cdc.gov/niosh/topics/snakes/default.html. Published June 28, 2021. Accessed December 15, 2021.
- Armstrong J. Identification and control of snakes in Alabama. Alabama Cooperative Extension System. https://www.aces.edu/blog/topics/forestry-wildlife/identification-and-control-of-snakes-in-alabama/. Published October 5, 2020. Accessed December 16, 2021.
- 3. White J, Danzl DF, Traub SJ. Snakebites worldwide: Management. UpToDate. https://www.uptodate.com/contents/snakebites-worldwide-management. Published July 14, 2020. Accessed December 15, 2021.
- 4. Lavonas, E.J., Ruha, AM., Banner, W. et al. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 11, 2 (2011). https://doi.org/10.1186/1471-227X-11-2
- 5. CROFAB Crotalidae Polyvalent Immune Fab (ovine) Package Insert. U.S. Food and Drug Administration. https://www.fda.gov/media/74683/download. Published 2000. Accessed December 15, 2021.

4&anchor=H3&source=see\_link#H3. Published March 3, 2020. Accessed December 16, 2021.

- 6. CROFAB Crotalidae Polyvalent Immune Fab (ovine). CroFab. https://crofab.com/. Published 2021. Accessed December 15, 2021.
- 7. ANAVIP. ANAVIP [crotalidae immune F(ab')<sub>2</sub> (equine)]. https://anavip-us.com/. Published October 1, 2021. Accessed December 16, 2021.
- 8. Bush SP, Ruha AM, Seifert SA, et al. Comparison of F(ab')<sub>2</sub> versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial. Clin Toxicol (Phila). 2015;53(1):37-45.
- 9. Blahd W, Adam Husney. Snakebite: Symptoms of a pit viper bite. University of Michigan Health: Michigan Medicine. https://www.uofmhealth.org/health-library/th1427. Published February 26, 2020. Accessed December 16, 2021.
- Seifert SA, Danzl DF, Traub SJ. Bites by Crotalinae snakes (rattlesnakes, water moccasins [cottonmouths], or copperheads) in the United States: Clinical manifestations, evaluation, and diagnosis. UpToDate. https://www.uptodate.com/contents/bites-by-crotalinae-snakes-rattlesnakes-water-moccasins-cottonmouths-or-copperheads-in-the-unitedstates-clinical-manifestations-evaluation-and-diagnosis?sectionName=APPEARANCE+AND+GEOGRAPHICAL+DISTRIBUTION&topicRef=659

**Ascension**